SwedishAmerican First in Rockford to Offer ICD with Diagnostic Tool to Predict Heart Failure
SwedishAmerican is pleased to announce it now offers implantable cardioverter defibrillators (ICDs) to its patients who suffer from heart disease. Developed by Boston Scientific and validated by clinical trials, HeartLogic Diagnostic is the first and only heart failure implantable device that provides an approximate 34 days advanced notice of an impending heart failure event. SwedishAmerican is the only hospital in Rockford to offer this new diagnostic tool to heart patients.
HeartLogic provides continuous measurement of early worsening signs of heart failure by combining data from sensors evaluating heart sounds, heart rate, respiration, activity levels and thoracic impedance. If the ICD were to go off, the cardiologist would be contacted and a detailed report would be sent. The physician would decide if the patient would need to be hospitalized or if the patient’s treatment needs to be readjusted.
“Heart failure affects more than 5.7 million people in the U.S. which accounts for thousands of hospitalizations and numerous deaths each year,” said SwedishAmerican Electrophysiologist Dr. John Kaminski. “This new technology can technically predict heart failure events weeks before they happen. We’re glad we can offer HeartLogic to our patients to help them avoid a lengthy hospital stay or even sudden death.”
The HeartLogic Diagnostic is part of Boston Scientific's Resonate family of ICDs and cardiac resynchronization therapy defibrillator (CRT-D) systems. Use of the new devices was approved by the Food and Drug Administration (FDA) in 2017.
For more information on HeartLogic, visit www.bostonscientific.com or contact the SwedishAmerican Heart Institute at (779) 696-5888.